Publications

Journal Articles

  1. & The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care
  2. & A case series of DKA occurring in patients receiving treatment with SGLT-2 inhibitors. Diabetes, Obesity and Metabolism 20(7), 1800-1801.
  3. & A retrospective observational study of people with Type 1 diabetes with self-reported severe hypoglycaemia reveals high level of ambulance attendance but low levels of therapy change and specialist intervention. Diabetic Medicine
  4. & Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease. Circulation 137(20), 2179-2183.
  5. & Clinical risk factors predicting genital fungal infections with sodium–glucose cotransporter 2 inhibitor treatment: The ABCD nationwide dapagliflozin audit. Primary Care Diabetes
  6. & Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism
  7. & Real-world clinical experience of Xultophy in the management of patients with type 2 diabetes in a secondary care clinic. Diabetes & Metabolic Syndrome: Clinical Research & Reviews
  8. & Managing hyperglycaemia in patients with diabetes and diabetic nephropathy–chronic kidney disease Summary of recommendations 2018. British Journal of Diabetes 18(2), 78-89.
  9. & Poor glycaemic control is associated with reduced exercise performance and oxygen economy during cardio-pulmonary exercise testing in people with type 1 diabetes. Diabetology & Metabolic Syndrome 9(1)
  10. & Semaglutide. GLP-1 receptor agonist, Treatment of type 2 diabetes. Drugs of the Future 42(8), 479
  11. & Cardiovascular events and all-cause mortality associated with sulfonylureas compared to other antihyperglycaemic drugs: A Bayesian meta-analysis of survival data. Diabetes, Obesity and Metabolism
  12. & Self-monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes (The SMBG Study): study protocol for a randomised controlled trial. BMC Endocrine Disorders 17(1)
  13. & Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology
  14. & Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 193229681773512
  15. & Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. The Lancet Diabetes & Endocrinology 5(5), 355-366.
  16. & Cardiovascular safety of liraglutide for the treatment of Type 2 diabetes. Expert Opinion on Drug Safety
  17. & Association of British Clinical Diabetologists (ABCD) and Renal Association clinical guidelines: Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease. British Journal of Diabetes 17(4), 160-164.
  18. & Mechanism of cardiovascular disease benefit of glucagon-like peptide 1 agonists. Cardiovascular Endocrinology 7(1), 18-23.
  19. & Omarigliptin for the treatment of type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy 17(14), 1947-1952.
  20. & Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine
  21. & Management of type 2 diabetes: the current situation and key opportunities to improve care in the UK. Diabetes, Obesity and Metabolism
  22. & LEADER-4. Journal of Hypertension 34(6), 1140-1150.
  23. & Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics of Eastern and Western European Participants with Established Cardiovascular Disease in the LEADER Trial. Journal of Diabetes & Metabolism 07(02)
  24. & Clinical use of the co-formulation of insulin degludec and insulin aspart. International Journal of Clinical Practice 70(8), 657-667.
  25. & Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, dc161525
  26. & LEADER 5: prevalence and cardiometabolic impact of obesity in cardiovascular high-risk patients with type 2 diabetes mellitus: baseline global data from the LEADER trial. Cardiovascular Diabetology 15(1)
  27. & Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial. Diabetes Care, dc142883
  28. & Impact of single and multiple sets of resistance exercise in type 1 diabetes. Scandinavian Journal of Medicine & Science in Sports 25(1), e99-e109.
  29. & Similar risk of exercise-related hypoglycaemia for insulin degludec compared with insulin glargine in patients with type 1 diabetes: a randomised cross-over trial. Diabetes, Obesity and Metabolism, n/a-n/a.
  30. & Simulated games activity vs continuous running exercise: A novel comparison of the glycemic and metabolic responses in T1DM patients. Scandinavian Journal of Medicine & Science in Sports, n/a-n/a.
  31. & Insulin Degludec Versus Insulin Glargine in Type 1 and Type 2 Diabetes Mellitus: A Meta-Analysis of Endpoints in Phase 3a Trials. Diabetes Therapy 5(2), 435-446.
  32. & Reductions in resistance exercise-induced hyperglycaemic episodes are associated with circulating interleukin-6 in Type 1 diabetes. Diabetic Medicine 31(8), 1009-1013.
  33. & One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. Journal of Diabetes and its Complications 27(5), 492-500.
  34. & Efficacy and Safety of Insulin Degludec in a Flexible Dosing Regimen vs Insulin Glargine in Patients With Type 1 Diabetes (BEGIN: Flex T1): A 26-Week Randomized, Treat-to-Target Trial With a 26-Week Extension. Journal of Clinical Endocrinology & Metabolism 98(3), 1154-1162.
  35. et. al. Association Testing of Previously Reported Variants in a Large Case-Control Meta-analysis of Diabetic Nephropathy. Diabetes 61(8), 2187-2194.
  36. & Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Diabetes Care 35(7), 1446-1454.
  37. & Isomaltulose Improves Postexercise Glycemia by Reducing CHO Oxidation in T1DM. Medicine & Science in Sports & Exercise 43(2), 204
  38. & An increased frequency of NK cell receptor and HLA-C group 1 combinations in early-onset type 1 diabetes. Diabetologia 54(12), 3062-3070.
  39. & Association between the adiponectin promoter rs266729 gene variant and oxidative stress in patients with diabetes mellitus. European Heart Journal 30(10), 1263
  40. & Hypertriglyceridaemia is associated with an increased likelihood of albuminuria in extreme duration (> 50 years) Type 1 diabetes. Diabetic Medicine 25(10), 1234
  41. & Genetic association analyses of non-synonymous single nucleotide polymorphisms in diabetic nephropathy. Diabetologia 51(11), 1998-2002.
  42. & Angiotensin-Receptor Blockade versus Converting–Enzyme Inhibition in Type 2 Diabetes and Nephropathy. New England Journal of Medicine 351(19), 1952-1961.
  43. & The rising incidence of childhood type 1 diabetes and reduced contribution of high-risk HLA haplotypes. The Lancet 364(9446), 1699-1700.